Clinical Trial Update: Nebulized Aztreonam for Prevention of Gram Negative Ventilator-associated Pneumonia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating nebulized aztreonam to prevent gram-negative ventilator-associated pneumonia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ventilator-associated Pneumonia

Drugs mentioned

• Aztreonam (aztreonam)

Snippet

Sponsor: Hospital Universitari Joan XXIII de Tarragona. | Conditions: Ventilator Associated Pneumonia, Prevention | Phase 2, Phase 3 | Status: TERMINATED